Literature DB >> 15583278

Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients.

Brigitte Fauroux1, Nicholas Hart, Samira Belfar, Michèle Boulé, Isabelle Tillous-Borde, Damien Bonnet, Edouard Bingen, Annick Clément.   

Abstract

The aim of the study was to evaluate the impact of Burkholderia cepacia on cardiovascular status and mortality in cystic fibrosis. Seven patients infected with B. cepacia were matched with 31 patients not infected with this organism for gender, age, height, weight, genotype, and percent predicted forced expiratory volume in one second, partial arterial oxygen pressure, and pancreatic sufficiency status. The pulmonary artery systolic pressure, as assessed by transthoracic echocardiography, was significantly higher in patients infected with B. cepacia (61.3 +/- 17.2 mm Hg) than in controls (37.3 +/- 13.9 mm Hg; P = 0.02), and the mean acceleration time was significantly lower (77 +/- 33 ms versus 108 +/- 25 ms; P = 0.02). The 6-month mortality was significantly higher in patients infected with B. cepacia (57% versus 16%; P = 0.02). Six of the seven patients infected with B. cepacia harbored the same ribotype (genomovar II, B. multivorans). Pulmonary hypertension was significantly more frequent in patients infected by B. cepacia and could contribute to the increased mortality rate.

Entities:  

Mesh:

Year:  2004        PMID: 15583278      PMCID: PMC535237          DOI: 10.1128/JCM.42.12.5537-5541.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.

Authors:  C Chaparro; J Maurer; C Gutierrez; M Krajden; C Chan; T Winton; S Keshavjee; M Scavuzzo; E Tullis; M Hutcheon; S Kesten
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

2.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

3.  Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension.

Authors:  M Fujita; J M Shannon; C G Irvin; K A Fagan; C Cool; A Augustin; R J Mason
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-01       Impact factor: 5.464

4.  Burkholderia cepacia in cystic fibrosis. Variable disease course.

Authors:  D D Frangolias; E Mahenthiralingam; S Rae; J M Raboud; A G Davidson; R Wittmann; P G Wilcox
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

5.  Altered respiratory epithelial cell cytokine production in cystic fibrosis.

Authors:  T L Bonfield; M W Konstan; M Berger
Journal:  J Allergy Clin Immunol       Date:  1999-07       Impact factor: 10.793

6.  Right ventricular dysfunction in adult severe cystic fibrosis.

Authors:  V G Florea; N D Florea; R Sharma; A J Coats; D G Gibson; M E Hodson; M Y Henein
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

7.  Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease.

Authors:  E Osika; J M Cavaillon; K Chadelat; M Boule; C Fitting; G Tournier; A Clement
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

8.  Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes.

Authors:  S M Zughaier; H C Ryley; S K Jackson
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

9.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

10.  Echocardiography in cystic fibrosis: A proposed scoring system.

Authors:  L A Lester; A C Egge; V S Hubbard; C S Camerini-Otero; R J Fink
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

View more
  11 in total

Review 1.  Bloodstream infections after solid-organ transplantation.

Authors:  Antonios Kritikos; Oriol Manuel
Journal:  Virulence       Date:  2016-01-14       Impact factor: 5.882

2.  Effects of lung transplantation on inpatient end of life care in cystic fibrosis.

Authors:  Elisabeth P Dellon; Margaret W Leigh; James R Yankaskas; Terry L Noah
Journal:  J Cyst Fibros       Date:  2007-05-03       Impact factor: 5.482

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Assessment of microbiological diagnostic procedures for respiratory specimens from cystic fibrosis patients in German laboratories by use of a questionnaire.

Authors:  Laura Häfner; Georg Peters; Barbara C Kahl
Journal:  J Clin Microbiol       Date:  2014-01-03       Impact factor: 5.948

5.  The mgtC gene of Burkholderia cenocepacia is required for growth under magnesium limitation conditions and intracellular survival in macrophages.

Authors:  Kendra E Maloney; Miguel A Valvano
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 6.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

7.  Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States.

Authors:  Kathleen J Ramos; Bradley S Quon; Kevin J Psoter; Erika D Lease; Nicole Mayer-Hamblett; Moira L Aitken; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2015-12-17       Impact factor: 5.482

8.  Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis.

Authors:  Thibaud Damy; Pierre-Régis Burgel; Jean-Louis Pepin; Pierre-Yves Boelle; Claire Cracowski; Marlène Murris-Espin; Raphaele Nove-Josserand; Nathalie Stremler; Tabassome Simon; Serge Adnot; Brigitte Fauroux
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

9.  Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.

Authors:  Kate Skolnik; Austin Nguyen; Ranjani Somayaji; Christina S Thornton; Barbara Waddell; Michael G Surette; Harvey R Rabin; Michael D Parkins
Journal:  BMC Pulm Med       Date:  2015-12-12       Impact factor: 3.317

10.  Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Authors:  Kate Skolnik; Austin Nguyen; Christina S Thornton; Barbara Waddell; Tyler Williamson; Harvey R Rabin; Michael D Parkins
Journal:  BMC Infect Dis       Date:  2017-10-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.